MedPage Today on MSN
Cemdisiran siRNA therapy demonstrates efficacy in myasthenia gravis
Investigational treatment improves outcomes without complete complement blockade ...
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...
Olverembatinib, an investigational multikinase inhibitor (approved in China for CML), inhibits Src-family kinases (e.g., Lyn, ...
Your home is a treasure chest of items that, with a little creativity, can find a new purpose in your backyard. Before you ...
Morning Overview on MSN
GLP-1 pioneers test obesity drugs that work even without GLP-1 signaling
For the past three years, nearly every breakthrough in obesity medicine has traced back to a single class of drugs: GLP-1 ...
If your answer is “never” or “only in my dreams,” then you clearly haven’t been to Rickwood Caverns State Park in Warrior, ...
The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
Jazz Pharmaceuticals plc today announced that the Company and its partners will present three rapid oral and seven poster presentations at the American Society of Clinical Oncology (ASCO) Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results